Clinical Report: Modulation of Smooth Muscle Cell Phenotype Induced by Immune Checkpoint Inhibitors

Overview

Nivolumab, an immune checkpoint inhibitor, induces significant changes in vascular smooth muscle cells (SMCs) that may increase atherosclerotic cardiovascular disease (ASCVD) risk. This study highlights the role of HSF1 and HMGCR activation in SMC phenotypic modulation.

Background

Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but are associated with increased ASCVD risk, independent of cholesterol levels. Understanding the mechanisms behind this risk is crucial for managing cardiovascular health in cancer survivors. Recent findings suggest that SMCs play a significant role in the atherosclerotic process linked to ICI therapy.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• Nivolumab activates heat shock factor 1 (HSF1) in cultured human SMCs.
• HSF1 activation leads to increased activation of HMG-CoA reductase (HMGCR) and accumulation of cholesteryl esters.
• Nivolumab treatment activates endoplasmic reticulum (ER) stress, particularly through PERK signaling.
• SMC phenotypic modulation associated with atherosclerosis is induced by nivolumab.
• Neutralization and knockdown of PD-1, as well as pravastatin treatment, can reverse the effects of nivolumab.

Clinical Implications

The findings indicate that patients receiving ICIs may experience changes in SMC activity and cholesterol metabolism.

Conclusion

Nivolumab's effects on SMCs and cholesterol metabolism provide insights into the cardiovascular risks associated with ICIs.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Author(s)/Org, Source, Year -- Title
6. Author(s)/Org, Source, Year -- Title
7. Author(s)/Org, Source, Year -- Title
8. Author(s)/Org, Source, Year -- Title
9. Author(s)/Org, Source, Year -- Title
10. Author(s)/Org, Source, Year -- Title
11. Author(s)/Org, Source, Year -- Title
12. Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton's Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance: A Report of the American College of Cardiology Solution Set Oversight Committee - PubMed
13. 2025 ESC Guidelines for the management of myocarditis and pericarditis | European Heart Journal | Oxford Academic
14. Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement - PubMed
15. ESC 365 - Multimodality imaging in the detection and management of coronary and peripheral arterial disease in patients with cancer receiving cardiotoxic antineoplastic treatments: A clinical consensus statement of the ESC Council of Cardio-Oncology and the European Association of Cardiovascular Imaging (EACVI) of the ESC
16. 26-A-20974-ACC ADVERSE ATHEROSCLEROTIC-RELATED CARDIOVASCULAR EVENTS FOLLOWING IMMUNE-CHECKPOINT INHIBITOR THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS | JACC
17. Accelerated atherosclerosis associated with immune checkpoint inhibitors: a systematic review and meta-analysis of pre-clinical studies - ScienceDirect
18. The immune checkpoint inhibitor avelumab increases aortic inflammation on [18F]FDG PET/CT: A retrospective cohort study - PubMed
19. Immune checkpoint inhibitors: Unravelling atherosclerotic cardiovascular risk - PubMed